Amyotrophic lateral sclerosis (ALS) increasingly converges on a shared biology: collapse of nuclear TDP-43 and FUS functions,
maladaptive stress granule persistence, and impaired protein quality control.1
6 7 This mechanism page focuses on
how defects in RNA metabolism,
proteostasis, and genome maintenance reinforce one another across sporadic and familial ALS.
Pathogenic variants in C9orf72, SOD1, TARDBP, FUS, and NEK1 alter RNA handling and protein turnover in motor
neurons.3 4 8 Loss of nuclear TDP-43 disrupts cryptic exon repression and splicing fidelity,
including pathways
required for axonal maintenance and synaptic resilience.2 7 In parallel, cytoplasmic TDP-43 and dipeptide repeat proteins derived from C9orf72 repeat expansion
overload autophagy, ubiquitin-proteasome system, and lysosomal clearance.
ALS-associated proteotoxic stress is tightly linked to disrupted mitochondrial quality control. Defects in TBK1- and OPTN-dependent
mitophagy impair removal of damaged mitochondria, increasing reactive oxygen species and RNA oxidation stress.5 Axonal transport vulnerability further amplifies this state: impaired trophic signaling and cargo trafficking in
long corticospinal and lower motor neuron projections can accelerate distal denervation.9
This mechanism helps explain why ALS presents as a systems-level degeneration despite diverse initiating mutations. RNA instability and
proteostasis overload first reduce cellular adaptive reserve in vulnerable motor neurons. Once reserve is
exhausted, DNA damage signaling, mitochondrial dysfunction, and glial stress responses become self-reinforcing loops that drive rapid
progression.1 6
The same mechanism also clarifies overlap with Frontotemporal Dementia (FTD). C9orf72 and TDP-43 pathology span ALS-FTD spectra, indicating that cell-type context and network architecture modulate a largely shared molecular engine.3 4
Priority intervention points include:
Current studies increasingly combine longitudinal biomarkers, genotype-defined cohorts, and mechanism-specific endpoints to determine whether molecular rescue translates to slower functional decline. High-value open areas include combined RNA-splicing plus proteostasis interventions, and early-stage trials in pre-symptomatic or minimally symptomatic carriers of high-risk variants.
The following resources provide additional data on genes and proteins related to Amyotrophic Lateral Sclerosis (ALS):
The study of Als Rna Metabolism And Proteostasis Failure has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 36%